Quest Diagnostics Declares Quarterly Cash Dividend - Aug 18, 2020

Quest Diagnostics, the world’s leading provider of diagnostic information services, announced that its Board of Directors declared a quarterly cash dividend of $0.56 per share, payable on October 21, 2020 to shareholders of record of Quest Diagnostics common stock on October 6, 2020.

SECAUCUS, N.J., Aug. 18, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.56 per share, payable on October 21, 2020 to shareholders of record of Quest Diagnostics common stock on October 6, 2020.

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

About COVID-19 Testing by Quest Diagnostics

Quest Diagnostics is at the forefront of response to the COVID-19 pandemic, working to broaden access to laboratory insights to help us all lead healthier lives. We provide both molecular diagnostic and antibody serology tests to aiding the diagnosis of COVID-19 and immune response. Our COVID-19 test services are based on tests that have received or are expected to receive FDA emergency use authorization and which also meet our high standards for quality. We provide data on COVID-19 testing to various federal and state public health authorities, including the Centers for Disease Control and Prevention, and participate in studies with government and private institutions, aiding COVID-19 public health response and research. Through our team of dedicated phlebotomists, couriers, air fleet team, and laboratory professionals, Quest Diagnostics won’t stop until quality testing is broadly available to patients and communities across the United States.

For more information about the latest developments with our COVID-19 testing, visit: newsroom.questdiagnostics.com/COVIDTestingUpdates

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-declares-quarterly-cash-dividend-301114436.html

SOURCE Quest Diagnostics

Company Codes: NYSE:DGX

MORE ON THIS TOPIC